Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.

Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR.

JAMA Neurol. 2018 Sep 1;75(9):1080-1088. doi: 10.1001/jamaneurol.2018.1212.

PMID:
29813147
2.

Protecting confidentiality in human research.

Adinoff B, Conley RR, Taylor SF, Chezem LL.

Am J Psychiatry. 2013 May;170(5):466-70. doi: 10.1176/appi.ajp.2012.12050595. No abstract available.

PMID:
23632832
3.

Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.

Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL.

J Clin Psychopharmacol. 2013 Feb;33(1):118-20. doi: 10.1097/JCP.0b013e3182793843. No abstract available. Erratum in: J Clin Psychopharmacol. 2016 Feb;36(1):26.

4.

Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.

Houston JP, Kohler J, Bishop JR, Ellingrod VL, Ostbye KM, Zhao F, Conley RR, Poole Hoffmann V, Fijal BA.

J Clin Psychiatry. 2012 Aug;73(8):1077-86. doi: 10.4088/JCP.11m06916.

PMID:
22967772
5.

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis.

Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M, Conley RR.

Neuropsychiatr Dis Treat. 2012;8:259-66. doi: 10.2147/NDT.S25662. Epub 2012 Jun 18.

6.

Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra.

Perez-Costas E, Melendez-Ferro M, Rice MW, Conley RR, Roberts RC.

Front Psychiatry. 2012 Apr 9;3:31. doi: 10.3389/fpsyt.2012.00031. eCollection 2012.

7.

Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.

Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, Culler SD.

J Med Econ. 2012;15(3):531-47. doi: 10.3111/13696998.2012.662923. Epub 2012 Feb 21.

PMID:
22304338
8.

Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Boggs DL, Kelly DL, McMahon RP, Gold JM, Gorelick DA, Linthicum J, Conley RR, Liu F, Waltz J, Huestis MA, Buchanan RW.

Schizophr Res. 2012 Feb;134(2-3):207-10. doi: 10.1016/j.schres.2011.11.009. Epub 2011 Dec 3.

9.

Researcher experiences with IRBs: a survey of members of the American College of Neuropsychopharmacology.

Wisner KL, Conley RR, Taylor SF, Kosten T, Rapaport MH, Brown LS.

IRB. 2011 Sep-Oct;33(5):14-20. No abstract available.

PMID:
22043746
10.

Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.

Stauffer VL, Song G, Kinon BJ, Ascher-Svanum H, Chen L, Feldman PD, Conley RR.

Schizophr Res. 2012 Feb;134(2-3):195-201. doi: 10.1016/j.schres.2011.09.028. Epub 2011 Oct 21.

PMID:
22019076
11.

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia.

Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ.

Clinicoecon Outcomes Res. 2011;3:9-14. doi: 10.2147/CEOR.S16061. Epub 2011 Jan 11.

12.

Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims.

Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC, Conley RR, Dwivedi Y.

J Psychiatr Res. 2012 Jan;46(1):57-63. doi: 10.1016/j.jpsychires.2011.08.006. Epub 2011 Sep 8.

13.

Striatal mitochondria in subjects with chronic undifferentiated vs. chronic paranoid schizophrenia.

Somerville SM, Conley RR, Roberts RC.

Synapse. 2012 Jan;66(1):29-41. doi: 10.1002/syn.20981. Epub 2011 Oct 11.

PMID:
21905126
14.

Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.

Fijal BA, Stauffer VL, Kinon BJ, Conley RR, Hoffmann VP, Witte MM, Zhao F, Houston JP.

J Clin Psychiatry. 2012 Mar;73(3):367-71. doi: 10.4088/JCP.10m06507. Epub 2011 Jul 12.

PMID:
21813073
15.

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.

Ruberg SJ, Chen L, Stauffer V, Ascher-Svanum H, Kollack-Walker S, Conley RR, Kane J, Kinon BJ.

BMC Psychiatry. 2011 Feb 9;11:23. doi: 10.1186/1471-244X-11-23.

16.

Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.

Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Montgomery W, Conley RR.

Curr Med Res Opin. 2011 Apr;27(4):713-30. doi: 10.1185/03007995.2011.554533. Epub 2011 Jan 25. Review.

PMID:
21265593
17.

Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.

Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu F, Feldman S, Ball MP, Wehring HJ, McMahon RP, Huestis MA, Heishman SJ, Warren KR, Buchanan RW.

J Clin Psychopharmacol. 2011 Feb;31(1):86-91. doi: 10.1097/JCP.0b013e318204825b.

19.

Mitochondria in the striatum of subjects with schizophrenia.

Somerville SM, Conley RR, Roberts RC.

World J Biol Psychiatry. 2011 Feb;12(1):48-56. doi: 10.3109/15622975.2010.505662. Epub 2010 Aug 10.

PMID:
20698738
20.

Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response.

Somerville SM, Lahti AC, Conley RR, Roberts RC.

Synapse. 2011 Mar;65(3):215-24. doi: 10.1002/syn.20838.

21.

Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine.

Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, Wonodi I, McMahon RP, Buchanan RW.

Neuropsychopharmacology. 2010 Oct;35(11):2274-83. doi: 10.1038/npp.2010.101. Epub 2010 Jul 21.

22.

Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.

Kelly DL, Feldman S, Boggs DL, Gale E, Conley RR.

Compr Psychiatry. 2010 May-Jun;51(3):298-302. doi: 10.1016/j.comppsych.2009.07.003. Epub 2009 Aug 27.

PMID:
20399340
23.
24.

Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.

Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, Warren KR, Conley RR.

J Clin Psychiatry. 2010 Mar;71(3):304-11. doi: 10.4088/JCP.08m04718yel. Epub 2010 Jan 12.

25.

The cost of relapse and the predictors of relapse in the treatment of schizophrenia.

Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR.

BMC Psychiatry. 2010 Jan 7;10:2. doi: 10.1186/1471-244X-10-2.

26.

The burden of depressive symptoms in people with schizophrenia.

Conley RR.

Psychiatr Clin North Am. 2009 Dec;32(4):853-61. doi: 10.1016/j.psc.2009.09.001.

PMID:
19944888
27.

Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1).

Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, Pandey GN.

Int J Neuropsychopharmacol. 2009 Nov;12(10):1337-54. doi: 10.1017/S1461145709990575.

PMID:
19835659
28.

Overestimating the prevalence of subtherapeutic dosing of atypical antipsychotics.

Stensland MD, Ascher-Svanum H, Lawson AH, Conley RR.

J Clin Psychiatry. 2009 Aug;70(8):1189-90; author reply 1190-91. doi: 10.4088/JCP.08lr04936. No abstract available.

PMID:
19758530
29.

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia.

Fijal BA, Kinon BJ, Kapur S, Stauffer VL, Conley RR, Jamal HH, Kane JM, Witte MM, Houston JP.

Pharmacogenomics J. 2009 Oct;9(5):311-8. doi: 10.1038/tpj.2009.24. Epub 2009 May 19.

PMID:
19451915
30.

A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.

Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D, Nelson M, Gold JM, Ball MP, Feldman S, Liu F, Conley RR.

J Clin Psychiatry. 2009 Apr;70(4):518-25. Epub 2009 Apr 7.

PMID:
19358788
31.

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Conley RR, Culler SD.

Cost Eff Resour Alloc. 2009 Apr 7;7:4. doi: 10.1186/1478-7547-7-4.

32.

Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response.

Roberts RC, Roche JK, Conley RR, Lahti AC.

Synapse. 2009 Jun;63(6):520-30. doi: 10.1002/syn.20623.

33.

Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis.

Regenold WT, Phatak P, Marano CM, Sassan A, Conley RR, Kling MA.

Biol Psychiatry. 2009 Mar 15;65(6):489-94. doi: 10.1016/j.biopsych.2008.11.010. Epub 2008 Dec 21.

34.

Fatty acid composition of the postmortem prefrontal cortex of adolescent male and female suicide victims.

McNamara RK, Jandacek R, Rider T, Tso P, Dwivedi Y, Roberts RC, Conley RR, Pandey GN.

Prostaglandins Leukot Essent Fatty Acids. 2009 Jan;80(1):19-26. doi: 10.1016/j.plefa.2008.10.002. Epub 2008 Dec 6.

PMID:
19064316
35.

Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients.

Regenold WT, Hisley KC, Phatak P, Marano CM, Obuchowski A, Lefkowitz DM, Sassan A, Ohri S, Phillips TL, Dosanjh N, Conley RR, Gullapalli R.

Bipolar Disord. 2008 Nov;10(7):753-64. doi: 10.1111/j.1399-5618.2008.00626.x.

36.

The effects of galantamine on psychopathology in chronic stable schizophrenia.

Conley RR, Boggs DL, Kelly DL, McMahon RP, Dickinson D, Feldman S, Ball MP, Buchanan RW.

Clin Neuropharmacol. 2009 Mar-Apr;32(2):69-74. doi: 10.1097/WNF.0B013E31816F2795.

37.

Neurotrophin receptor activation and expression in human postmortem brain: effect of suicide.

Dwivedi Y, Rizavi HS, Zhang H, Mondal AC, Roberts RC, Conley RR, Pandey GN.

Biol Psychiatry. 2009 Feb 15;65(4):319-28. doi: 10.1016/j.biopsych.2008.08.035. Epub 2008 Oct 19.

38.

Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims.

Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi Y.

Int J Neuropsychopharmacol. 2008 Dec;11(8):1047-61. doi: 10.1017/S1461145708009000. Epub 2008 Jul 9.

PMID:
18611289
39.

GSK-3beta gene expression in human postmortem brain: regional distribution, effects of age and suicide.

Pandey GN, Dwivedi Y, Rizavi HS, Teppen T, Gaszner GL, Roberts RC, Conley RR.

Neurochem Res. 2009 Feb;34(2):274-85. doi: 10.1007/s11064-008-9770-1. Epub 2008 Jun 28.

PMID:
18584322
40.

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.

Kelly DL, Conley RR, Love RC, Morrison JA, McMahon RP.

Ann Clin Psychiatry. 2008 Apr-Jun;20(2):71-8. doi: 10.1080/10401230802017050.

PMID:
18568578
41.

Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia.

Wonodi I, Hong LE, Stine OC, Mitchell BD, Elliott A, Roberts RC, Conley RR, McMahon RP, Thaker GK.

Am J Med Genet B Neuropsychiatr Genet. 2009 Mar 5;150B(2):282-9. doi: 10.1002/ajmg.b.30811.

42.

Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.

Kelly DL, McMahon RP, Weiner E, Boggs DL, Dickinson D, Conley RR, Buchanan RW.

Schizophr Res. 2008 Aug;103(1-3):161-8. doi: 10.1016/j.schres.2008.04.027. Epub 2008 Jun 11.

43.

Differential synaptic changes in the striatum of subjects with undifferentiated versus paranoid schizophrenia.

Roberts RC, Roche JK, Conley RR.

Synapse. 2008 Aug;62(8):616-27. doi: 10.1002/syn.20534.

PMID:
18509852
44.

Postmortem brain tissue of depressed suicides reveals increased Gs alpha localization in lipid raft domains where it is less likely to activate adenylyl cyclase.

Donati RJ, Dwivedi Y, Roberts RC, Conley RR, Pandey GN, Rasenick MM.

J Neurosci. 2008 Mar 19;28(12):3042-50. doi: 10.1523/JNEUROSCI.5713-07.2008.

45.

Quetiapine at high doses for the treatment of refractory schizophrenia.

Boggs DL, Kelly DL, Feldman S, McMahon RP, Nelson MW, Yu Y, Conley RR.

Schizophr Res. 2008 Apr;101(1-3):347-8. doi: 10.1016/j.schres.2008.01.013. Epub 2008 Feb 20. No abstract available.

46.

Maintaining informed consent validity during lengthy research protocols.

Prentice KJ, Appelbaum PS, Conley RR, Carpenter WT.

IRB. 2007 Nov-Dec;29(6):1-6. No abstract available.

PMID:
18237078
47.

Comparison of clozapine response for inpatients in the research setting versus routine clinical practice.

Boggs DL, Kelly DL, Love RC, McMahon RP, Conley RR.

Psychiatr Q. 2008 Jun;79(2):111-9. doi: 10.1007/s11126-008-9067-1. Epub 2008 Jan 24.

48.

5-Lipoxygenase in the Prefrontal Cortex of Suicide Victims.

Uz T, Dwivedi Y, Pandey GN, Roberts RC, Conley RR, Manev R, Manev H.

Open Neuropsychopharmacol J. 2008 Jan 1;1:1-5.

49.

Lower phosphoinositide 3-kinase (PI 3-kinase) activity and differential expression levels of selective catalytic and regulatory PI 3-kinase subunit isoforms in prefrontal cortex and hippocampus of suicide subjects.

Dwivedi Y, Rizavi HS, Teppen T, Zhang H, Mondal A, Roberts RC, Conley RR, Pandey GN.

Neuropsychopharmacology. 2008 Sep;33(10):2324-40. Epub 2007 Dec 12.

50.

Challenge to atypical antipsychotic drug effect on cognition.

Carpenter WT, Conley RR.

Am J Psychiatry. 2007 Dec;164(12):1910-1; author reply 1911-2. No abstract available.

PMID:
18056250

Supplemental Content

Loading ...
Support Center